Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

nal trials and/or larger randomized trials which we expect to commence planning for soon."

"These two studies, which represent surprising single agent activity, as well as a very encouraging combination effect with Vidaza, increase our enthusiasm for epigenetic intervention in cancer and the potential for MGCD0103," said Patrick J. Mahaffy, President and Chief Executive Officer of Pharmion Corporation.

Clinical Trial Details

"A Phase II Study of MGCD0103, a Novel Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor in Patients with Relapsed or Refractory Hodgkin Lymphoma" (Abstract #8000, Trial 010). Oral, monotherapy treatment with MGCD0103 demonstrated substantial anti-tumor activity in patients with relapsed or refractory Hodgkin's lymphoma. In this study, patients were given MGCD0103 as a single-agent three times per week for four weeks (one cycle) at a starting dose of 110mg. The objectives of this study are to determine the response and disease control rates, as well as safety, toxicity and pharmacodynamic markers. As of May 2007, 22 patients were enrolled and, of these, 20 were evaluable for response analysis.

All patients enrolled in this study had prior chemotherapy ranging from two to nine prior therapies with the median being four. In addition, 59 percent of enrolled patients had prior radiation treatment and 86 percent had prior autologous bone marrow transplant. Overall, eight patients showed objective responses (two complete responses and six partial responses) and nine experienced stable disease (one patient beyond six months) resulting in a response rate of 40 percent and a disease control rate (CR+PR+SD™ 6 months) of 45 percent in this highly-refractory or relapsed population. In total, 75 percent of patients experienced reduction in tumor size; 60 percent experienced tumor reduction greater than 30 percent. Fifty percent of patients remained on treatment for four or more cycles.

Fatigue and gastrointe
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:2/27/2015)... -- Report Details   Translational ... progress, and predicted revenues ,Where is the market for ... prospects for this market and related technologies? Visiongain,s brand ... to 2025, discussing data, opportunities and prospects. ... medicine : cell-based therapies that aim to restore function ...
(Date:2/27/2015)... Feb. 27, 2015  In recognition of Rare Disease ... the global bleeding disorders community, CSL Behring ... units (IUs) of protein therapies to the World Federation ... organization which has worked to improve the lives of ... donation supports the WFH,s Global Alliance for Progress (GAP) ...
(Date:2/27/2015)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the fourth quarter and full year ended December ... year for PTC. We are now a growing commercial-stage ... in the rare disease space," stated Stuart W. Peltz, ... proud to bring the first treatment for Duchenne muscular ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
... McLaren Health Care and its Great,Lakes Cancer ... medical,minds to share the latest work underway around ... October 11th symposium, hosted by,McLaren and GLCI, was ... oncologist whose work in sentinel node mapping for,colorectal ...
... Changes Induced by ... in Patients with Celiac Disease, Additional Data Indicates Potential in ... Alba Therapeutics Corporation,presented results from two clinical studies this week ... Data from,study CLIN 1001-004, the first Phase IIa trial conducted ...
Cached Medicine Technology:News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6
(Date:2/27/2015)... Transfinder is very pleased to announce that ... to Work for in New York State for 2015. ... great work environment. People spend a lot of time ... There’s no reason why we can’t have fun while ... and CEO of Transfinder, a leading provider of intelligent ...
(Date:2/27/2015)... Cocaine is an extreme stimulant, causing the ... hostility. In a joint effort between Australian and American ... may soon rejoice in what has been a breakthrough ... response of cocaine, according to 7 News ... that the brain is continually communicating with the immune ...
(Date:2/27/2015)... Local lice removal service reports that cases ... areas of Pinecrest, Key Biscayne, Coral Gables, Miami Beach and ... attempt to isolate and eradicate the problem. , Among ... may be partly to blame. As kids put their heads ... contact that can allow for the spread of head lice. ...
(Date:2/27/2015)... Cucamonga, CA (PRWEB) February 27, 2015 ... STEM”U”LATE Your Mind: Pi Day event on March 14, ... about RDI-Engineering’s services, demonstrations on how to use engineering ... The event will be hosted by Moreno Valley College’s ... STEM Student Success Center (SSC) in hopes to encourage ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Prescription ... the U.S. Drug Enforcement Agency (DEA). Today, ... organizations continue to utilize the “Take-Back” guidelines for ... the FDA. , Eufaula Prescription Drug Disposal Event ... Industrial Drive in Eufaula, Oklahoma as the “Take-Back” ...
Breaking Medicine News(10 mins):Health News:Transfinder Named a Best Company to Work for in New York State 2Health News:A New Study May Have an Answer to Treating Cocaine Addiction 2Health News:A New Study May Have an Answer to Treating Cocaine Addiction 3Health News:Parents frustrated as selfies continue to contribute to the spread of head lice in Miami according to the largest Lice Removal Service in Miami called Lice Troopers 2Health News:RDI-Engineering Participates in STEM”U”LATE Your Mind Event to Host Educational Exhibition 2Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 2Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 3
... latest NHS news it is said that the breast cancer drug ... patients. But this is not happy news to the grieving family ... breast cancer. But NHS officials denied her the drug which led ... ,By profession she was an advertising art director from ...
... a plan to improve the bedside manners of would-be doctors. ... will be "embedded" with patients suffering from a chronic illness ... ,This program will be compulsory for the students and ... the US. "I think it would be ideal to have ...
... shaky from terror bombings and the 2004 tsunami, was ... parts of this Javanese cultural city, a prime tourist ... its cultural history, temples and vibrant arts and crafts ... overseas tourists. ,"We're suffering another setback," said ...
... claimed that ancient trees could provide clues to the pattern of ... Pingri, 75, from Guangdong Academy of Sciences has opined that rising ... but in fact was a part of the cyclical order of ... ancient trees, I discovered the temperature throughout history has risen and ...
... Initiated by their professor - high school and college students ... ,Isolation and characterisation of 30 macrophages has been made ... Genetics issue of June 9, 2006 has a report of ... the University of Pittsburgh. The report is about the characterization ...
... colleagues at the Indiana University Medical Center, Indianapolis say ... into having unwanted sex //. ,Unwanted sex ... researchers write in the June issue of the Archives ... result in risk for sexually transmitted infections and pregnancies. ...
Cached Medicine News:Health News:Indonesian Tourism on Downward Trend After Java Quake 2